4[5]Wang Q,Ding ZH,Liu JK,et al.Xanthohumol,a novel anti-HIV-1 agent purified from Hop Humulus lupulus[J].Antiviral Res,2004,64:189-194.
5[6]Wang JH,Tam SC,Huang H,et al.Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduces potency in vitro[J].Biochem Biophys Res Commun,2004,317:965-971.
2Corbett JW, Ko SS, Rodgers JD, et al. Inhibition of clinically rele- vant mutant variants of HIV-1 by quinazolinone non-nucleoside re- verse transcriptase inhibitors[ J]. J Med Chem ,2000,43 (10) :2019 -30.
3Echeverria P, Negredo E, Carosib G, et al. Similar antiviral effica- cy and tolerability between efavirenz and lopinavir/ritonavir, admin- istered with abacavir/lamivudine (Kivexa) , in antiretroviral-naive patients : A 48-week, multicentre, randomized study [ J ]. Antiviral Research ,2010,85 (2) :403 - 8.
4Thompson AS, Corley EG, Huntington MF, et al. Use of an ephed- rine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone:asymmetric synthesis of the reverse transcfiptase inhibitor L-743,726[ J]. Terrflhpdron Letters, 1995,36(49) :8937 --40.
5Radescaa LA, Loa YS, Moorea JR, et al. Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266 [ J ]. Synthetic Communications, 1997,27 (24) :4373 - 84.
6Jiang B, Feng Y. Enantioselective alkynylafion of a prochiral ketone catalyzed by C2-symmetric diaminodiols [ J ]. Tetrahedron Lett, 2002,43 (16) :2975 - 7.
7Chinkov N, Warm A, Carreira EM. Asymmetric Autocatalysis Ena- bles an Improved Synthesis of Efavirenz [ J ]. Angew Chem Int Ed, 2011,50(13) : 2957 -61.
8Anusuya C, Moore JR, Pierce ME, et al. In situ recycling of chiral ligand and surplus nucleophile for a noneatalytic reaction : amplifi- cation of process throughput in the asymmetric addition step of efa- virenz (DMP 266)[J]. Organic Process Research & Development, 2003,7 (3) :324 - 8.
